1. 1) Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry, 67, 146–154 (2010).
2. 2) Carlson SJ, Fallon EM, Kalish BT, Gura KM, Puder M. The role of the omega-3 fatty acid DHA in the human life cycle. JPEN J. Parenter. Enteral Nutr., 37, 15–22 (2013).
3. 3) Mossaheb N, Schloegelhofer M, Schaefer MR, Fusar-Poli P, Smesny S, McGorry P, Berger G, Amminger GP. Polyunsaturated fatty acids in emerging psychosis. Curr. Pharm. Des., 18, 576–591 (2012).
4. 4) Song C, Shieh CH, Wu YS, Kalueff A, Gaikwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer’s disease: Acting separately or synergistically? Prog. Lipid Res., 62, 41–54 (2016).
5. 5) Bondi CO, Taha AY, Tock JL, Totah NK, Cheon Y, Torres GE, Rapoport SI, Moghaddam B. Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol. Psychiatry, 75, 38–46 (2014).